2 88

Cited 18 times in

Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia.

Authors
 Sang Kyun Sohn ; Suk Joong Oh ; Seon Yang Park ; Joon Ho Moon ; Deog Yeon Jo ; Dae Young Zang ; Eun Kyung Park ; Yeo Kyeoung Kim ; Hyeoung Joon Kim ; Chul Soo Kim ; Jinny Park ; Moo Rim Park ; Hawk Kim ; Min Kyoung Kim ; Myung Soo Hyun ; Ki Seong Eom ; Joon Seong Park ; June Won Cheong ; Yoo Hong Min ; Jong Ho Won ; Hong Ghi Lee ; Ho In Kim ; Sung Soo Yoon ; Dong Hwan Kim ; Chul Won Jung ; Soo Mee Bang ; Young Don Joo ; Joo Seop Chung ; Hun Mo Ryoo ; Byung Soo Kim 
Citation
 Leukemia & Lymphoma, Vol.52(6) : 1024~1029, 2011 
Journal Title
 Leukemia & Lymphoma 
ISSN
 1042-8194 
Issue Date
2011
Abstract
To investigate the correlation of trough imatinib mesylate (IM) levels with cytogenetic or molecular responses, we measured trough IM levels in patients with chronic myeloid leukemia, chronic phase (CML-CP), at 6 months of treatment with a standard dose of IM. Eighty-seven newly diagnosed patients with CML-CP were prospectively enrolled. Seventy-eight patients (89.7%) showed an optimal response (complete or partial cytogenetic response) at 6 months. Trough IM levels were 1378 ± 725 ng/mL. When categorized into two groups, there was a statistically significant difference in numbers of patients with optimal and suboptimal responses at 6 months (group with  <1000: 80.6% vs. 19.4%;  ≥ 1000: 94.6% vs. 5.4%; p = 0.032), and in numbers of patients with early major molecular response (early-MMR) and without MMR at 6 months (group with  <1000: 3.2% vs. 96.8%;  ≥ 1000: 21.4% vs. 78.6%; p = 0.047). In conclusion, the incidence of optimal cytogenetic response or early-MMR in patients with CML-CP treated with IM for 6 months was significantly higher in those with a trough level of  ≥ 1000 compared with those with a level of <1000. Dose escalation of IM can be one option in patients with CML showing suboptimal response or resistance to the standard dose of IM, especially with low trough plasma IM levels (<1000 ng/mL).
URI
http://ir.ymlib.yonsei.ac.kr/handle/22282913/93761
DOI
10.3109/10428194.2011.563885
Appears in Collections:
1. 연구논문 > 1. College of Medicine > Dept. of Internal Medicine
Yonsei Authors
사서에게 알리기
  feedback
Link
 http://informahealthcare.com/doi/abs/10.3109/10428194.2011.563885
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse